
• Reported GAAP EPS of -$0.15 down -42.31% YoY • Reported revenue of $79.43M up 9.04% YoY • AngioDynamics raised its full year FY 2026 guidance for net sales to $312-$314 million and Adjusted EBITDA to $8.0-$10.0 million, while maintaining expectations for positive free cash flow.
Bullish
AngioDynamics achieved strong Med Tech growth and profitability, secured key regulatory approvals for its Mechanical Thrombectomy portfolio, and strengthened its financial position with positive cash flow and resolved litigation.
Bearish
AngioDynamics faces leadership transition with its CEO's upcoming retirement, anticipates a $4.0 million to $6.0 million tariff impact in FY26, and reported a GAAP net loss of $6.4 million for the quarter.